Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection

Dijkman, K. ; Aguilo, N. (Universidad de Zaragoza) ; Boot, C. ; Hofman, S.O. ; Sombroek, C.C. ; Vervenne, R.A.W. ; Kocken, C.H.M. ; Marinova, D. (Universidad de Zaragoza) ; Thole, J. ; Rodríguez, E. ; Vierboom, M.P.M. ; Haanstra, K.G. ; Puentes, E. ; Martin, C. (Universidad de Zaragoza) ; Verreck, F.A.W.

Resumen: To fight tuberculosis, better vaccination strategies are needed. Live attenuated Mycobacterium tuberculosis-derived vaccine, MTBVAC, is a promising candidate in the pipeline, proven to be safe and immunogenic in humans so far. Independent studies have shown that pulmonary mucosal delivery of Bacillus Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine available today, confers superior protection over standard intradermal immunization. Here we demonstrate that mucosal MTBVAC is well tolerated, eliciting polyfunctional T helper type 17 cells, interleukin-10, and immunoglobulins in the airway and yielding a broader antigenic profile than BCG in rhesus macaques. Beyond our previous work, we show that local immunoglobulins, induced by MTBVAC and BCG, bind to M. tuberculosis and enhance pathogen uptake. Furthermore, after pulmonary vaccination, but not M. tuberculosis infection, local T cells expressed high levels of mucosal homing and tissue residency markers. Our data show that pulmonary MTBVAC administration has the potential to enhance its efficacy and justifies further exploration of mucosal vaccination strategies in preclinical efficacy studies.

Idioma: Inglés

DOI: 10.1016/j.xcrm.2020.100187

Año: 2021

Publicado en: Cell reports medicine 2, 1 (2021), 100187 [18 pp]
ISSN: 2666-3791

Factor impacto JCR: 16.988 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 5 / 140 = 0.036 (2021) - Q1 - T1
Categ. JCR: CELL BIOLOGY rank: 17 / 195 = 0.087 (2021) - Q1 - T1

Factor impacto CITESCORE: 7.1 - Biochemistry, Genetics and Molecular Biology (Q2)

Factor impacto SCIMAGO: 5.956 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
Financiación: info:eu-repo/grantAgreement/EC/H2020/730964/EU/European Vaccine Research and Development Infrastructure/TRANSVAC2

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Proy. investigación HQA (Dpto. Microb.Ped.Radio.Sal.Pú.)